Chemistry: analytical and immunological testing – Lipids – triglycerides – cholesterol – or lipoproteins
Patent
1994-12-12
1997-05-20
Bhat, Nina
Chemistry: analytical and immunological testing
Lipids, triglycerides, cholesterol, or lipoproteins
435 4, G01N 3392
Patent
active
056311680
ABSTRACT:
An antemortem diagnostic test for neurodegenerative disease, particularly Alzheimer's disease, is disclosed. The method of the invention involves the collection of a sample of bodily fluid; the analysis of the concentration of neuronal membrane phospholipids and phospholipid metabolites, or the ratio of a phospholipid to its metabolite, in the sample; and the correlation of the concentration or the ratio to the corresponding value from control samples. The method can be used to determine the presence or the possibility that an individual can develop a neurodegenerative disease, such as Alzheimer's disease; to follow the course of neurodegenerative disease in an individual; and to validate the efficacy of a drug used to treat a neurodegenerative disease.
REFERENCES:
patent: 4874694 (1989-10-01), Gandy et al.
patent: 4918062 (1990-04-01), Lodi
patent: 5006462 (1991-04-01), Gahaz
patent: 5051410 (1991-09-01), Wurtman et al.
Nitsch, R.M. et al., "Evidence for a membrane defect in Alzheimer disease brain," Proc. Natl. Acad. Sci. USA 89:1671-1675 (Mar. 1992).
Pettegrew, J.W. et al., "Correlation of Phosphorus-31 Magnetic Resonance Spectroscopy and Morphological Findings in Alzheimer's Disease," Archives of Neurology 45(10): 1093-1096 (1988).
Kwee, I.L. et al., "Elevation in relative levels of brain membrane unsaturated fatty acids in Alzheimer's disease: high resolution proton spectroscopic studies of membrane lipid extracts," Magn. Reson. Med. 21(1):49-54 (1991). (From Chemical Abstracts 116(19): Abstract No. 192004 (1992)).
Dyrks, T. et al., "Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease," EMBO J. 7(4):949-957 (1988).
Blusztajn, Jan K., et al., "Abnormal Phospholipid Metabolism In Neurodegenerative Diseases: Elevations in Glycerophosphocholine and Glycerophosphoethanolamine Levels in Brain of Alzheimer's Disease but not in Down Syndrome Patients," Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, (T. Nagatsu et al., etc., Plenum Press) I:133-138 (1990).
Skinner, E. Roy, et al., "Lipid Composition of Different Regions of the Brain in Patients with Alzheimer's Disease," Biochemical Society Transactions 17(1):213-214 (1988).
Kawakatsu, Shinobu et al., "Acetylcholinesterase Activities and Monoamine Metabolite Levels in the Cerebrospinal Fluid of Patients with Alzheimer's Disease," Biol. Psychiatry 28: 387-400 (1990).
Bisso, G.M., et al., "Molecular Forms of Cholinesterases in CSF of Alzheimer's Disease/Senile Dementia of Alzheimer Type Patients and Matched Neurological Controls," Life Sciences 38:561-567 (1986).
Blusztajn, Jan K., et al., "Levels of Phospholipid Catabolic Intermediates, Glycerophosphocholine and Glycerophosphoethanolamine, Are Elevated in Brains of Alzheimer's Disease but not of Down's Syndrome Patients," Brain Research 536:240-244 (1990).
S oderberg, M., et al., "Lipid Composition in Different Regions of the Brain in Alzheimer's Disease/Senile Dementia of Alzheimer's Type," Journal of Neurochemistry 59:1646-1653 (1992).
Maire, Jean-Claude E., et al., "Choline Production from Choline-Containing Phospholipids: A Hypothetical Role in Alzheimer's Disease and Aging," Prog. NeuroPsychopharmacol. & Biol. Psychiat. 8:637-642 (1984).
Reinikainen, K. J., et al., "Cholinergic Deficit in Alzheimer's Disease: A Study Based on CSF and Autopsy Data," Neurochemical Research 13(2):135-146 (1988).
Wurtman, Richard J., et al., "Use of Choline in Cholinergic Neurons to Form Acetylcholine or Phosphatidylcholine: Implications for the Pathogenesis of Age-Related Memory Disorders," Aging Brain and Dementia: New Trends in Diagnosis and Therapy 54:215-258 (1990).
Elble, Rodger, et al., "Choline Levels are Increased in Cerebrospinal Fluid of Alzheimer Patients," Neurobiology of Aging 10:45-50 (1989).
Atack, John R., et al., "Cerebrospinal Fluid Cholinesterases in Aging and in Dementia of the Alzheimer Type," Ann. Neurol. 23:161-167 (1988).
Growdon, J.H. and M. Logue, "Choline, HVA, and 5-HIAA Levels in Cerebrospinal Fluid of Patients with Alzheimer's Disease," Alzheimer's Disease: A Report of Progress (Aging 19:35-43), edited by S. Corkin et al., Raven Press, New York (1982).
Blusztajn, J.K. et al., "The Possible Role of Neuronal Choline Metabolism in the Pathopsysiology of Alzheimer's Disease," Adv. Basic Res. Ther. Proc. Meet. Int. Study Group Treat Mem. Disord. Assoc. Aging 3rd:183-98 (1984).
Hollander et al, Neubiology of Aging, vol. 7, pp. 367-387 1986 "Antemortem Markers of AD".
Miller et al "Neurobiological Aging" vol. 12(1) pp. 61-64, 1991 Differences in Red Blood Cell . . . AD.
Nitsch et al, Annals of New York Academy of Science "Alterations of Phospholipid Metabolites . . . AD".
Blusztajn et al, Brain Research, "Levels of Phospholipid . . . Down's Syndrome Patients", 1990, pp. 240-244.
Growdon John H.
Nitsch Roger M.
Wurtman Richard J.
Bhat Nina
Massachusetts Institute of Technology
LandOfFree
Antemortem diagnostic test for Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antemortem diagnostic test for Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antemortem diagnostic test for Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1723279